196 related articles for article (PubMed ID: 32468451)
1. In Silico and In Vivo Studies on Quercetin as Potential Anti-Parkinson Agent.
Boyina HK; Geethakhrishnan SL; Panuganti S; Gangarapu K; Devarakonda KP; Bakshi V; Guggilla SR
Adv Exp Med Biol; 2020; 1195():1-11. PubMed ID: 32468451
[TBL] [Abstract][Full Text] [Related]
2. Intervention of mitochondrial dysfunction-oxidative stress-dependent apoptosis as a possible neuroprotective mechanism of α-lipoic acid against rotenone-induced parkinsonism and L-dopa toxicity.
Abdin AA; Sarhan NI
Neurosci Res; 2011 Dec; 71(4):387-95. PubMed ID: 21889550
[TBL] [Abstract][Full Text] [Related]
3. Quercetin potentiates L-Dopa reversal of drug-induced catalepsy in rats: possible COMT/MAO inhibition.
Singh A; Naidu PS; Kulkarni SK
Pharmacology; 2003 Jun; 68(2):81-8. PubMed ID: 12711835
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of the neuroprotective role of coenzyme Q10 with or without L-dopa in rotenone-induced parkinsonism.
Abdin AA; Hamouda HE
Neuropharmacology; 2008 Dec; 55(8):1340-6. PubMed ID: 18817789
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological evaluation of vanillic acid in rotenone-induced Parkinson's disease rat model.
Sharma N; Khurana N; Muthuraman A; Utreja P
Eur J Pharmacol; 2021 Jul; 903():174112. PubMed ID: 33901458
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotective Properties of Standardized Extracts of Hypericum perforatum on Rotenone Model of Parkinson's Disease.
Gómez del Rio MA; Sánchez-Reus MI; Iglesias I; Pozo MA; García-Arencibia M; Fernández-Ruiz J; García-García L; Delgado M; Benedí J
CNS Neurol Disord Drug Targets; 2013 Aug; 12(5):665-79. PubMed ID: 23469842
[TBL] [Abstract][Full Text] [Related]
8. Beneficial effects of natural phenolics on levodopa methylation and oxidative neurodegeneration.
Kang KS; Yamabe N; Wen Y; Fukui M; Zhu BT
Brain Res; 2013 Feb; 1497():1-14. PubMed ID: 23206800
[TBL] [Abstract][Full Text] [Related]
9. Introductory remarks: Catechol-O-methyltransferase inhibition--an innovative approach to enhance L-dopa therapy in Parkinson's disease with dual enzyme inhibition.
Nissinen E
Int Rev Neurobiol; 2010; 95():1-5. PubMed ID: 21095456
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
[TBL] [Abstract][Full Text] [Related]
11. Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.
Najib J
Clin Ther; 2001 Jun; 23(6):802-32; discussion 771. PubMed ID: 11440283
[TBL] [Abstract][Full Text] [Related]
12. Role of catechol-O-methyltransferase (COMT)-dependent processes in Parkinson's disease and L-DOPA treatment.
Espinoza S; Manago F; Leo D; Sotnikova TD; Gainetdinov RR
CNS Neurol Disord Drug Targets; 2012 May; 11(3):251-63. PubMed ID: 22483291
[TBL] [Abstract][Full Text] [Related]
13. β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity.
Huang L; Deng M; Zhang S; Lu S; Gui X; Fang Y
Biomed Pharmacother; 2017 Oct; 94():666-678. PubMed ID: 28787702
[TBL] [Abstract][Full Text] [Related]
14. Drugs for Parkinson's disease.
Treat Guidel Med Lett; 2013 Nov; 11(135):101-6. PubMed ID: 24165688
[TBL] [Abstract][Full Text] [Related]
15. L-dopa therapy for Parkinson's disease: past, present, and future.
Nagatsua T; Sawadab M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S3-8. PubMed ID: 19131039
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective Effect of Quercetin in Combination with Piperine Against Rotenone- and Iron Supplement-Induced Parkinson's Disease in Experimental Rats.
Sharma S; Raj K; Singh S
Neurotox Res; 2020 Jan; 37(1):198-209. PubMed ID: 31654381
[TBL] [Abstract][Full Text] [Related]
17. The effect of catechol-O-methyltransferase inhibition with entacapone on cardiovascular autonomic responses in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Sovijärvi A; Kaakkola S; Gordin A; Teräväinen H
Clin Neuropharmacol; 2001; 24(1):50-7. PubMed ID: 11290882
[TBL] [Abstract][Full Text] [Related]
18. Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline.
Davis TL; Roznoski M; Burns RS
Mov Disord; 1995 May; 10(3):349-51. PubMed ID: 7651456
[TBL] [Abstract][Full Text] [Related]
19. [The role of inhibitors of COMT and MAO-B in the therapy of Parkinson's disease].
Woitalla D; Krüger R; Lorenzl S; Müller T; Oelwein G; Storch A; Wolz M; Wüllner U
Fortschr Neurol Psychiatr; 2020 Sep; 88(9):620-633. PubMed ID: 32588409
[TBL] [Abstract][Full Text] [Related]
20. The pharmacology of Parkinson's disease: basic aspects and recent advances.
Da Prada M; Keller HH; Pieri L; Kettler R; Haefely WE
Experientia; 1984 Nov; 40(11):1165-72. PubMed ID: 6437857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
